-
Paty, DW., et al. (1998) Multiple sclerosis. Philadelphia: F.A. Davis; 1998.
-
Zajicek, JP., et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517-1526.
-
Zajicek, JP., et al. (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76:1664–1669.
-
Wade, DT., et al. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434–441.
-
Rog, DJ., et al. (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65:812–819.
-
Kavia, RB., et al. (2010) Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 83:1125–1132.
-
Zajicek, JP., et al (2012) Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 83:1125–1132.
-
Fisher, RS., et al. (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475-82.
-
O’Connell, BK., et al. (2017) Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav 70:341–8.
-
Suraev, A., et al. (2017) An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav 70:334–40.
-
Kwan, P., et al. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51:1069–77.
-
Dos Santos, RG., et al. (2015) Phytocannabinoids and epilepsy. J Clin Pharm Ther 40:135–43.
-
Dos Santos, RG., et al. (2015) Phytocannabinoids and epilepsy. The Journal of Clinical Pharmacy and Therapeutics.